亚洲人成电影在线小说网色,国产av一区二区精品凹凸,免费特级黄毛片在线成人观看,亚洲最大国产成人综合网站,久久国产情侣露脸精品,国产成人亚洲精品,国产精品久久久久久一区二区三区,成人a级视频在线播放,国产精品无码无卡无需播放器,久久久久久久久久亚洲精品

2024/12/10 SHINE

Locally-Developed Gene Editing Technology Cures Boy with Serious Blood Disorder

A 14-year-old boy with serious thalassemia has recovered due to a locally-developed innovative gene editing technology, the Children's Hospital of Fudan University said on Monday.

Details

2024/12/05 Correctseq

CorrectSequence Therapeutics to Participate in the 66th ASH Annual Meeting and Exposition

Dec 5, 2024, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aims to use the innovative gene editing technology to help people with severe diseases, announc

Details

2024/07/22 Correctseq

The First Clinical Gene Editing Therapy to Treat An Overseas Patient in China

On July 20, 2024, Shanghai, China, CorrectSequence Therapeutics Co., Ltd. (Correctseq) announced a significant milestone in their base editing therapy CS-101 for transfusion-dependent β-thalassemia. U

Details

2024/07/19 Correctseq

CS-101 Clinical Result Included in EHA2024 Scientific Congress Report

Recently, the European Hematology Association (EHA) released the EHA2024 Scientific Congress Report titled "EHA Perspectives on Emerging Technologies in Hematology". As the world's firs

Details

2024/06/06 Correctseq

CorrectSequence Therapeutics to Participate in EHA2024 Hybrid Congress

June 6, 2024, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aims to use the innovative gene editing technology to help people with severe diseases, announ

Details

2024/06/03 Correctseq

CorrectSequence Therapeutics to Participate in BIO International Convention 2024

May 29, 2024, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aims to use the innovative gene editing technology to help people with severe diseases, announ

Details

2024/04/13 Correctseq

CorrectSequence Therapeutics to Participate in the 27th Annual Meeting of American Society of Gene & Cell Therapy

April 12, 2024, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aims to use the innovative gene editing technology to help people with severe diseases, anno

Details

2024/04/02 Correctseq

CorrectSequence Therapeutics’ Base Editing Drug "CS-101 Injection" Obtains IND Approval from the NMPA

CorrectSequence Therapeutics’ (Correctseq’s) base editing drug "CS-101 Injection" targeting transfusion-dependent β-thalassemia has obtained IND approval from the National Medical Products Administration (NMPA) of China on April 2, 2024 (acceptance number: CXSL2400021). This is the Chinese first base editing therapy with β-thalassemia. Correctseq is initiating the Phase 1 clinical study for CS-101 (clincialtrials.gov reference # NCT06291961).

Details